Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge

Shares of Biogen Inc.
BIIB, -0.89%
bounced 1.7% in premarket trade Monday, after the drugmaker disclosed that it set a new $5.0 billion stock repurchase program, without an expiration date. The new program is in addition to the $1.7 billion remaining under the program set in August 2018. The new buyback announcement comes after the stock plummeted 32.4% to close Friday at the lowest level since June 2016, after the company said it would discontinue its phase 3 trials of its Alzheimer's treatment, citing results of an interim analysis of trial data. Based on Friday's stock closing price of $216.71, the total buyback authorization would represent about 30.92 million shares, or 15.7% of the shares outstanding. Biogen's stock has shed 16.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF
IBB, +0.41%
has gained 2.7% and the S&P 500
SPX, +0.14%
has advanced 8.2%.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.